Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their products, with significant business development (BD) transactions announced[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% increase year-on-year, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise, with a projected increase of 33-38% for NAND Flash products due to supply constraints[36] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - The goal is to achieve a 30% share of renewable energy in total power generation by 2030, indicating significant growth potential for the solar and wind energy sectors[46]

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their advancements, with significant business development (BD) transactions reported[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% year-on-year increase, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise due to increased demand from AI servers, with NAND Flash supply expected to decrease by 41.7% in 2026[35] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - By 2030, renewable energy generation is expected to account for approximately 30% of total power generation, indicating significant growth potential in the solar and wind sectors[46]

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 截至2026年1月28日 13:15，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 1.70%，兴齐眼药上涨1.39%，艾力斯上涨0.67%；英科医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 东海证券指出，商务部等九部门联合印发的关于促进药品零售行业高质量发展的意见，从转型、支付、 供应、整合四大维度构建行业发展框架，推动行业从"单一卖药"向"健康服务"转型。政策明确鼓励兼并 重组与横向并购，叠加医保定点待遇与基层医疗机构平权、医保个人账户家庭共济等举措，将加速单体 药店出清，行业集中度有望加速提升；优化外配处方审核，打通线下药店处方堵点，允许企业自建药学 服务平台，加速处方外流和市场扩容；鼓励零售药店扩大经营范围，开展健康咨询、中医药文化、养老 照护、便民零售等，打造综合健康服务体。建议关注资金实力雄厚、并购整合能力强，合规运营与精细 ...

创新药概念局部活跃，消息面上，新修订的《中华人民共和国药品管理法实施条例》将于5月15日起施 行。国家药监局表示，这是条例实施二十多年来，首次全面修订。支持以临床价值为导向研究和创制新 药，提升仿制药质量和疗效。 中信证券研报称，2026年1月，阿里健康、京东健康两家头部医药电商平台相继正式发布面向医生的AI 医疗应用产品。看好头部医药电商平台凭借上游药企、下游C端用户资源，以及其母公司具备的AI基模 能力与产品能力，在ToD AI医疗应用领域脱颖而出，并率先跑通商业模式，实现AI医疗对主业的增收 赋能。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年1月28日 11:09，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，兴齐眼药领涨 1.42%，新和成上涨1.27%，片仔癀上涨0.27%；英科医疗领跌2.47%，华兰生物下跌2.22%，恩华药业下 跌2.22%。医疗创新ETF ...

海外市场的突破性拓展成为业绩增长的核心引擎。2025年全球生物医药BD交易总额达1356.55亿美元，涉及157起交易，中国首次超越美国成为全球BD交易 最活跃市场。龙头企业纷纷通过海外授权与市场扩张斩获增量，三生国健凭借与辉瑞达成的707项目合作，获得约28.90亿元首付款收入，预计2025年归母净 利润同比增长311.35%至29亿元。CXO龙头药明康德表现亮眼，预计2025年归母净利润191.51亿元，同比激增102.65%，其"一体化、端到端"CRDMO模式持 续吸引全球客户，海外订单复苏态势显著。通化东宝的国际化战略成效凸显，胰岛素制剂已在5个新兴市场国家获批，门冬胰岛素美国BLA获FDA受理，出 口收入成为业绩重要增长点。和众汇富观察发现，国产药企正从"快速跟进"向"全球新"输出转型，出海赛道逐渐成为板块估值提升的核心主线。 截至2026年1月26日，Wind数据显示已有逾90家A股生物医药公司披露2025年业绩预告，其中53家预计实现盈利，14家公司净利润增幅下限超100%，多家企 业实现扭亏为盈或大幅减亏。在行业景气度持续回暖、海外市场加速突破及政策红利密集释放的多重支撑下，A股生物医药板块正 ...

截至2026年1月28日 10:09，中证医药及医疗器械创新指数(931484)下跌0.45%。成分股方面涨跌互现， 片仔癀领涨1.57%，兴齐眼药上涨1.00%，新和成上涨0.80%；华兰生物领跌。医疗创新ETF(516820)最 新报价0.36元。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评 ...

Core Viewpoint - The A-share market is witnessing a significant increase in performance forecasts, with 1,201 listed companies disclosing their 2025 annual performance predictions, indicating a positive trend in various industries, particularly in non-ferrous metals, automotive, chemicals, and semiconductors [1][2]. Group 1: Performance Forecasts - A total of 1,201 listed companies have released performance forecasts, with 475 companies expecting positive results and 107 companies anticipating a doubling of net profit for 2025 [1][2]. - Among the companies that disclosed forecasts, 371 are expected to achieve a net profit exceeding 100 million yuan, 84 companies over 1 billion yuan, and 22 companies over 3 billion yuan [2]. - The performance of leading companies in the non-ferrous metals, automotive, chemicals, and semiconductor sectors has shown significant recovery [2]. Group 2: Institutional Research - Following the performance forecasts, many companies have attracted intensive institutional research, focusing on new and existing order volumes, progress on new production lines, and positive industry changes [3]. - Changhua Chemical reported that its carbon dioxide polyether project is nearing completion, with trial production expected in the first quarter of this year, pending approval [3][4]. - Chutian Technology noted that while competition remains fierce, it is gradually easing, with market concentration increasing and international market expansion becoming a new growth point [5]. Group 3: Emerging Industries - Institutions are increasingly focusing on emerging industries such as semiconductors and energy storage [6]. - Hemai Co. indicated that its energy storage business is experiencing rapid growth, with significant revenue increases expected in the coming years despite rising costs in the domestic market [6]. - Dongxin Co. mentioned that the niche memory market is seeing price increases due to supply constraints, with a positive outlook for its storage products [6].

Group 1 - A total of 1201 A-share listed companies have disclosed their 2025 annual performance forecasts, with 475 companies expecting positive results and 107 companies anticipating a net profit increase of over 100% year-on-year [1][2] - Among the companies that have released performance forecasts, 371 are expected to achieve a net profit of over 100 million yuan, with 84 companies projected to exceed 1 billion yuan and 22 companies over 3 billion yuan [2] - The industries showing significant performance recovery include non-ferrous metals, automotive and parts, chemicals, and semiconductors, with leading companies in these sectors performing exceptionally well [1][2] Group 2 - Following the performance forecasts, many listed companies have attracted intensive institutional research, focusing on new and existing order volumes, progress on new production lines, and positive changes in their respective industries [3][5] - Changhua Chemical's carbon dioxide polyether project is nearing completion, with trial production expected in the first quarter of this year, pending approval processes [3][4] - Companies like Chutian Technology have noted a gradual alleviation of intense competition in their industry, with market concentration increasing and international market expansion becoming a new growth point [5][6] Group 3 - HeMai Co. has reported rapid growth in its energy storage system business, with significant revenue increases expected in the coming years despite potential profit margin compression due to rising battery cell prices [6] - Dongxin Co. has indicated that niche memory products are experiencing price increases due to supply constraints, driven by an industry upcycle and shifts in production capacity towards higher-margin products [6]

A股业绩预告加速披露。数据显示，截至1月27日17时，A股共有1201家上市公司对外披露2025年全年业 绩预告，其中475家预喜，107家公司预计2025年全年归属于上市公司股东的净利润同比翻倍。从行业角 度看，有色金属、汽车与零配件、化工、半导体等行业相关上市公司业绩回暖较为明显，行业龙头公司 表现较为优异。 业绩预告发布后，不少上市公司获机构密集调研。从机构调研的内容看，机构普遍对上市公司新增及在 手订单量情况、新产线的建设进度、所在行业出现的积极变化较为关注。 ● 本报记者 董添 107家净利润翻倍 业绩预告发布后，不少上市公司获机构密集调研。从机构调研的内容看，机构普遍对上市公司新增及在 手订单量情况、新产线的建设进度、所在行业出现的积极变化较为关注。 对于二氧化碳聚醚项目一期的建设进度，长华化学（301518）在1月26日晚间披露的投资者关系活动记 录表中表示，项目目前处于工程建设尾期，正在为申请试生产、消防验收等做好各项准备工作，预计今 年一季度试生产，具体时间以相关审批手续的办结时间而定。公司全资子公司长华化学科技（连云港） 有限公司的二氧化碳聚醚项目总体规划是年产106万吨分期建设。公司计划 ...

Core Viewpoint - The A-share market is witnessing a significant increase in performance forecasts, with 1,201 listed companies disclosing their 2025 annual performance predictions, indicating a positive trend in various industries, particularly in non-ferrous metals, automotive, chemicals, and semiconductors [1][2]. Group 1: Performance Forecasts - A total of 1,201 listed companies have disclosed their performance forecasts, with 475 companies expecting positive results, and 107 companies anticipating a doubling of net profit for 2025 [1][2]. - Among the companies that have released forecasts, 371 expect a net profit of over 100 million yuan, 84 expect over 1 billion yuan, and 22 expect over 3 billion yuan [1]. - The companies with the highest expected net profits include Zijin Mining, Luoyang Molybdenum, WuXi AppTec, Luxshare Precision, Muyuan Foods, and Baofeng Energy [1]. Group 2: Net Profit Growth - Excluding companies that are turning losses into profits, 476 companies expect a minimum net profit growth of over 10%, with 107 expecting over 100%, and 25 expecting over 300% [2]. - Among the top ten companies by net profit, only one is expected to see a decline, while the others are projected to experience varying degrees of growth [2]. Group 3: Industry Trends - The performance recovery is particularly notable in the non-ferrous metals, automotive, chemicals, and semiconductor sectors, with leading companies in these industries showing strong results [1][2]. - Companies like Changhua Chemical are nearing the completion of their carbon dioxide polyether project, with expectations for trial production in the first quarter of the year, which is part of a larger plan to produce 1.06 million tons annually [3]. - Chu Tian Technology has reported that while competition remains fierce, it is gradually easing, with market concentration increasing and international market expansion becoming a new growth point [4]. Group 4: Institutional Research - Following the performance forecasts, many companies have attracted intensive institutional research, focusing on new and existing order volumes, new production line progress, and positive industry changes [1][2]. - Emerging industries such as semiconductors and energy storage are also receiving significant attention from institutional investors, with companies like Hemai Co. reporting rapid growth in their energy storage systems business [4].